ANRS MIE and the International Vaccine Institute: working together to improve access to vaccines

This collaboration focuses on 4 main areas:

• identifying research priorities and innovative approaches to combat emerging and re-emerging infectious diseases of common interest;
• provide technical support and build the human and technical capacity of partners in low- and middle-income countries to enhance the development of medical countermeasures;
• develop training programs and provide technical assistance to ANRS MIE partners;
• increase the impact and effectiveness of public health investments through better program coordination and alignment.

These orientations will be concretely implemented through the sharing of information and research results, the development of international research projects with funding for local partners, the provision of reciprocal expertise by and for staff members and associate experts from both institutions, the strengthening of advocacy and lobbying activities on key scientific strategies, etc.

About IVI:

The International Vaccine Institute (IVI) is an independent, international, non-profit organization founded to improve the health of children in developing countries through the use of new and improved vaccines. Working in collaboration with the international scientific community, public health organizations, governments and industry, IVI is involved in all areas of the vaccine spectrum, from the design of new vaccines in the laboratory to the evaluation of vaccines in the field. The organization concentrates its activities in countries where vaccines are most needed.

Initially created on the initiative of the United Nations Development Program, the International Vaccine Institute began official operations as an independent international organization in 1997. Its headquarters are in Seoul, South Korea.

Currently, the IVI is supported by 35 countries and the World Health Organization (WHO). The Institute’s mandate is to work on the development and introduction of vaccines specifically for populations in developing countries, focusing on the neglected diseases that affect these regions.